Featured releases

Biotech Startup Launches At-Home Genetic Health Insight Panel

Cambridge-Based Biotech Startup Unveils At-Home Genetic Health Insight Panel, Targets $5.1 Billion DTC Market

Cambridge, Mass. – November 25, 2025 Veritas Genomics today announced commercial availability of its GenomeInsight™ Health Panel, a saliva-based test that screens 30 clinically actionable genes tied to cardiovascular disease, hereditary cancers and adverse drug reactions. Priced at $399 and ordered through a telehealth physician included in the kit, consumers receive a bilingual PDF report and optional genetic counseling within 10–14 days of the sample arriving at the company’s CLIA-certified Boston laboratory.

The launch coincides with a surge in demand for personalized health data. The global direct-to-consumer genetic-testing market is projected to more than double from US $2.4 billion in 2025 to US $5.1 billion by 2032, driven by falling sequencing costs and a 20 % year-over-year increase in chronic-disease awareness campaigns.

“Consumers no longer want to wait for a crisis to understand their DNA,” said Dr. Karen Li, co-founder and chief executive of Veritas Genomics. “GenomeInsight™ closes the gap between curiosity and clinical utility by reporting only on genes with evidence-based intervention guidelines, then connecting customers to preventive care pathways through our partner network.”

The panel uses next-generation sequencing and proprietary bioinformatics to interrogate genes such as BRCA1/2, LDLR, MTHFR and CYP2C19, cross-referencing findings against the latest Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. Results are reviewed by a board-certified genetic counselor before release; flagged variants trigger a complimentary one-on-one consultation and a letter the customer can share with their primary-care provider.

Early adopters appear willing to pay for depth over breadth. A 2025 survey by the Personalized Medicine Coalition found 62 % of millennials would spend >$300 on a genetic test that informs drug dosing or early-detection strategies, up from 44 % in 2022. Veritas is betting the cohort will offset slower reimbursement adoption among insurers, which still classify most DTC panels as “investigational.”

The company has raised $18 million in Series A financing led by Andreessen Horowitz and has inked pilot programs with three regional health systems to integrate GenomeInsight™ data into electronic health records ahead of 2026 value-based-care contracts.

About Veritas Genomics

Veritas Genomics is a precision-health company founded in 2021 by veterans of the Human Genome Project and former clinicians from Mass General Brigham. The firm operates a CLIA-certified, CAP-accredited laboratory in Boston and a software engineering hub in Montreal. Its mission is to democratize access to clinically actionable genomic information while maintaining the highest standards of data security and medical ethics.